Company news
Hoth Therapeutics, Inc. news in 2023
Hoth Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami
December 26, 2023
Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies
December 4, 2023
Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT
November 13, 2023
Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery
October 4, 2023
FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients
October 1, 2023
Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia
September 12, 2023
Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
September 12, 2023
Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer Patients
September 10, 2023
Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexa
September 5, 2023
Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's Disease
August 8, 2023
Hoth Therapeutics Announces Major Milestone of First Patient Dosed in Phase 2a Clinical Trial
July 24, 2023
Hoth Therapeutics Receives Protocol Approval for HT-001 Cancer Therapeutic
July 18, 2023
Hoth Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial of HT-001 at Second Clinical Site
June 13, 2023
Hoth Therapeutics Announces Positive Preclinical Results of HT-ALZ treatment for Alzheimer's Disease
June 5, 2023
Hoth Therapeutics and Algorithm Sciences Terminate Letter of Intent to Merge
May 11, 2023
Hoth Therapeutics and Algorithm Sciences Execute Letter of Intent to Merge
April 25, 2023
Hoth Therapeutics Announces Collaboration with First Active Clinical Site for its Phase 2 Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy
March 7, 2023
Hoth Therapeutics Announces Increased Positive Results of its Alzheimer's Therapeutic HT-ALZ
February 7, 2023
Hoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy
January 24, 2023
Decks in 2023
- Investor Presentation (August 2023)
Investor deck · 33 slides · August 2023